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Stand-first: 
There are regular calls to introduce routine screening for group B Streptococcus colonisation 
in late pregnancy in the UK. In this paper, Seedat and colleagues argue that screening should 
not be introduced at present because of the potential harm from high levels of unnecessary 
treatment with antibiotic prophylaxis and the uncertainty of screening effectiveness.  
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Group B Streptococcus (Streptococcus agalactiae, GBS) is the commonest cause of neonatal 
sepsis and meningitis in many developed countries.1 In the UK, GBS causes invasive disease 
in the first six days of life (early onset GBS or EOGBS) in around 1 of every 2,000 live births.2 
3 To prevent EOGBS, intrapartum antibiotic prophylaxis (IAP), usually intravenous penicillin, 
is the recommended mainstay internationally. In the UK, a risk-based strategy is 
recommended, whereby pregnant women presenting with GBS risk factors are offered IAP 
during labour.4-7 
There are regular media and political calls to introduce universal antenatal GBS screening as 
an alternative means of selecting women for IAP. Advocates point to countries across 
Europe and North America where screening is recommended8-22 and where EOGBS 
reductions have been observed.23-25 However, when examining the evidence using 
established screening criteria,26 it becomes clear that the effectiveness of screening is 
uncertain and that screening has potential harms. Here, we explain the evidence-based 
reasons not to introduce universal screening in the UK based on UK National Screening 
Committee (UK NSC) evidence reviews and key papers published since,27 28 namely high 
levels of overtreatment, unknown potential hazards from screening and treatment with IAP, 
and uncertain benefit. 
Background 
GBS is a Gram-positive bacterium that colonises the gastrointestinal and genitourinary tract 
in approximately 20% of pregnant women.29-31 It usually causes no harm.9 However, if a 
woman is colonised at the time of labour, around 36% will transmit GBS to their neonate.32 
Crucially, the majority of neonates colonised with GBS will remain asymptomatic; however, 
about 3% will develop EOGBS disease.32 Neonates with EOGBS present with sepsis in 63% of 
cases, pneumonia in 24%, meningitis in 13%,3 and around 5% to 10% die as a result.2 3 33 
Neurological impairment is reported in up to 15.8% of EOGBS survivors,34-36 though long-
term outcomes are not well researched. The true burden of EOGBS is likely higher as most 
of the research only describes culture-confirmed cases while the infecting organism in 
approximately half of neonatal sepsis cases cannot be isolated.37 EOGBS is an important 
health condition causing considerable morbidity and mortality. 
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A risk-based strategy to prevent EOGBS has been recommended in the UK since 2003.4-7 
Pregnant women presenting with GBS risk factors of preterm labour, GBS colonisation, a 
previous infant with GBS disease, GBS bacteriuria, intrapartum fever, and chorioamnionitis 
are offered IAP.4-7 However, 65% of neonates with EOGBS do not have risk factors and are 
therefore not eligible for IAP.3 
Universal screening for GBS 
Universal screening involves the collection of specimens using rectovaginal swabs at 35 to 
37 weeks gestation, which are processed using selective culture media, to identify women 
colonised with GBS so that IAP can be offered to those testing positive.38 Therefore, 
screening would be offered to all term pregnant women and could detect some of the 65% 
of EOGBS cases without risk factors. 
Screening was first introduced in the US where the incidence of culture-confirmed EOGBS 
was around 1.7 per 1,000 live births. The incidence reduced to 0.4 in 2001 following the 
1996 recommendation that either a risk-based or screening strategy could be implemented. 
This reduced again to 0.3 in 2004 after the recommendation that screening should be 
implemented in 2002.24 25 Screening has continued since and incidence has most recently 
been reported to be 0.22 per 1000 live births.39 Most countries recommending screening 
have similarly seen a reduction or stabilisation in the incidence of EOGBS,23 40 though some 
have not.41 In the UK and Republic of Ireland, with no screening but risk based prevention, 
the incidence was much lower than the US before screening, at 0.57 per 1,000 live births 
(n=518 in 2014–15). However, there was a statistically significant increase from 0.48 in 
2000–01, before national guidelines were published,2 3 the reasons for which are unclear. 
Overdiagnosis and potential harm 
As identified above, only a small percentage of neonates born to women colonised with GBS 
will develop EOGBS. Therefore, the proposed screening programme would detect a large 
number of women who carry GBS and would be eligible for IAP when, if left untreated, their 
baby would not have developed EOGBS. Based on UK data, antenatal culture would 
correctly predict which babies develop EOGBS in around 2/1,000 (0.2%) pregnant women 
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(see figure 1, 205/126,159 in 2000–01 and 350/138,933 in 2014–15). This positive predictive 
value of the test of 0.2% is orders of magnitude worse than in other national screening 
programmes, and so would deliver an unacceptably high level of false positive results. A 
cost-effectiveness model published in 2007 also estimated that adding screening to risk-
based prevention would result in 99.8% overtreatment (increasing antibiotic use in 
pregnancy from 11% to 27%).42 Similarly, an Australian centre reported 1,191 women would 
need to be treated with IAP to prevent one case of EOGBS.43 Although the model contains 
some limitations because of evidence gaps, the estimates support the high levels of 
overtreatment that would occur when introducing screening. 
As 99.8% of pregnant women and their babies would be overtreated, an examination of 
potential harms is particularly important for GBS screening. A systematic review of 30 
studies found little evidence to quantify the potential harms of IAP to mothers and babies.44 
Although a range of adverse effects were investigated, studies specifically on GBS 
prophylaxis were observational and at risk of bias while 13 RCTs at lower risk of bias 
investigated antibiotics and regimens different to GBS prophylaxis. Key findings from the 
review were around changes in gut microbiota, long term functional impairment, and 
antibiotic resistance. 
There was consistent observational evidence that IAP for GBS prophylaxis alters neonatal 
gut microbiota.45-52 Gut microbiota changes have been associated with metabolic problems 
such as obesity and diabetes, atopic, inflammatory, and autoimmune problems such as 
asthma and necrotising enterocolitis, and autism.53-55 Separately, early antibiotic exposure 
has also been associated with these long-term clinical outcomes.53-56 However, it is 
unknown whether microbiota alterations specifically from GBS prophylaxis are associated 
with any long-term clinical outcomes. The impact of IAP on antibiotic resistance was 
inconsistent, with some evidence of an increase in the resistance of some antibiotics for 
some pathogens, with others showing no increase.50 57-61 Globally, the overwhelming 
majority of GBS isolates are susceptible to penicillin,62 however, in the US in 2005, 0.2% of 
GBS isolates were reaching the upper level of susceptibility for one or more beta-lactams.63 
In the era of antimicrobial resistance, such a widespread IAP strategy may be challenging in 
relation to the UK Department of Health and Social Care’s antimicrobial resistance strategy 
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to reduce unnecessary use of antibiotics.64 Finally, there was a particular lack of information 
on the long-term outcomes of IAP. There was evidence from only one RCT using antibiotics 
for spontaneous preterm labour, which found that antibiotic use was moderately associated 
with serious consequences of functional impairment at seven years of age.65 However, this 
study has applicability concerns as the antibiotics differed and were given for a longer 
duration. 
Maternal anaphylaxis is another important harm to consider as it has potentially fatal 
consequences. However, as it is rare, it is difficult to explore in well-designed studies other 
than very large RCTs. In the US, four anaphylactic cases associated with GBS prophylaxis 
were reported since the introduction of guidelines in 1996 up to 2010.66 In the UK, the rate 
of all-cause maternal anaphylaxis has been reported at 1.6 per 100,000 maternities (37 
cases in three years, 11 due to penicillin) and one was a result of GBS prophylaxis. Two 
mothers (5%) died and 14 (38%) mothers and 7 (41%) neonates required intensive care 
admission.67 68  
Other reported harms include neonatal respiratory distress,69 maternal thrush,70 and 
childhood atopic dermatitis.71 IAP during labour may also limit birth choices for women and 
medicalise labour.5 However, it is difficult to draw conclusions on the harms of screening as 
the evidence is based mainly on small observational studies, subject to bias, and/or have 
applicability concerns. 
Uncertain evidence on screening effectiveness 
The evidence on the clinical effectiveness of universal GBS screening is observational and 
focusses on incidence rather than clinical outcomes. There have been no randomised 
controlled trials (RCTs) assessing the effects of screening on the reduction of EOGBS 
incidence, clinical outcomes, or mortality. In the absence of RCTs, it is difficult to quantify 
the potential impact of adding screening to risk-based practice. 
A systematic review of nine observational studies from Turkey, Australia, and the US found 
that the odds of EOGBS under universal screening were 55% lower than under risk-based 
prevention for all neonates and term neonates alone (three studies).72 A recent study in a 
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UK maternity unit found that the rate of EOGBS fell from 0.99 per 1,000 live births in the 
risk-based period to 0.33 during the screening period; though, this was not statistically 
significant, and screening was instigated based on high incidence so there may have been 
regression to the mean.73 Additional analysis of mothers who were actually screened 
compared to the pre-screening period was reported as statistically significant (0.16 versus 
0.99 per 1,000 live births, RR 0.16, p<0.05). However, the mothers who accepted screening 
may have been systematically different and authors acknowledged that there were 
statistically significant differences in several maternal characteristics between the screening 
and risk-based periods. In a follow on study, the authors found that EOGBS incidence had 
increased to 1.79 per 1,000 live births after the cessation of screening, which was 
statistically significant when adjusting for ethnicity.74 Most observational evidence shows no 
difference in EOGBS mortality between risk-based and screening prevention,75-77 while the 
impact on long-term outcomes is unknown. However, these studies may be underpowered 
to detect differences in these rare outcomes. 
The risk of bias from observational study designs is well-documented due to confounding 
and the inability to determine cause and effect.78 79 The majority of studies on GBS 
screening compare the incidence of EOGBS during a period of screening with a historical 
control period (i.e. risk-based prevention) that precedes it.75-77 80-83 Risk of bias is higher in 
these studies as participants in the study and control period are not contemporaneous so 
other changes occurring between these periods may contribute to results. The few 
observational studies that compare screening to concurrent controls often retrospectively 
compare women with a culture result to all other women;84 85 this may be biased due to the 
risk of misclassification and that people who accept screening are systematically different to 
those who do not.72 86 Finally, as most studies only assess culture-confirmed EOGBS, 
changes in disease incidence may actually reflect a decreased likelihood of culturing GBS in 
the laboratory because of antibiotics in neonates’ blood as opposed to a true change.87 This 
distorts the impact of screening and may explain why, in studies examining culture-
confirmed EOGBS, a reduction in incidence is found between screening and risk-based 
prevention but in studies assessing mortality or all-cause neonatal sepsis, there is no 
difference. Studies exploring all-cause early-onset sepsis have been contradictory, 88-90 and 
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as mentioned above, studies on mortality may be underpowered to detect differences. As a 
result of the limitations, the effectiveness of universal GBS screening is uncertain. 
Conclusions 
GBS infection is an important health problem and more work to understand and prevent 
neonatal disease is required. Universal GBS screening is a complex area and the current 
evidence of uncertainty about whether screening would do more good than harm highlights 
the problem with introducing a new screening programme. Selective maternal culture is not 
an accurate predictor of EOGBS disease in neonates. If a GBS screening programme is 
implemented, it would offer all term pregnant women the culture test, but around 99.8% of 
screen-positive mothers (and their babies) would be overdiagnosed and unnecessarily 
receive IAP. The harm from widespread IAP to thousands of pregnant women and their 
babies is unknown while the evidence on the benefit from screening is uncertain due to 
lower quality studies with serious limitations. 
Recently, the Health Technology Assessment launched a call for an RCT assessing the 
effectiveness of GBS screening, which may address the uncertainty on the clinical benefits of 
screening. This should be complemented by research assessing the potential harms before 
we can be confident that universal screening is a safe undertaking. Additionally, research to 
more accurately identify the women at most risk of having a neonate with EOGBS could 
reduce the amount of overtreatment. Alternatively, advances are underway in the 
development of a GBS vaccine, which could avoid the concerns around screening and have 
the potential to prevent early and late onset GBS.91  
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Boxes  
 
Figure caption / legend:  
Figure 1. Natural history of GBS in a hypothetical cohort of term pregnant women in year 
2000 (no national prevention guideline) and 2014 (risk-based national prevention 
guideline). Under no national prevention guideline, 126,159 term pregnant women were 
colonised with GBS, but only 205 term neonates developed EOGBS, meaning screening 
would overtreat 125,954 (99.8%) of women with IAP in labour. 
Abbreviations: GBS Group B Streptococcus, EOGBS early-onset group B Streptococcus, intrapartum antibiotic prophylaxis, 
NPV Negative predictive value, PPV Positive predictive value 
Notes: Due to the uncertainties of the data, the numbers should be treated cautiously for a sense of scale but not as exact 
estimates.  Data estimates and sources: 
a. Pregnant women available for screening in 2000 and 2014: All live births taken from the Office for National 
Statistics,92 then elective caesarean sections and preterm births (<37 weeks) were removed from the cohort 
using HES estimates,93 94 as elective caesarean sections are not at risk of EOGBS and preterm births are not 
eligible for screening. Note: Rate for preterm births in 2000 is taken from 2004-05. 
b. Maternal GBS carriage: 22%.31  
c. Number of EOGBS disease cases and mortality taken from British Paediatric Surveillance Unit study.2 3 33 
Key messages 
 
1. Early-onset group B Streptococcus disease (< 7 days of life, EOGBS) is an 
important health problem and efforts should continue to better understand 
and prevent it.  
2. A universal antenatal culture screening programme cannot currently be 
recommended.  
3. Selective maternal culture is not an accurate test to predict EOGBS disease 
in neonates, and a lack of understanding about why some colonised mothers 
have a neonate with EOGBS limits the ability to identify a better approach. 
4. The current approach would offer all term pregnant women the culture test 
and lead to around 99.8% of screen-positive women and their babies 
receiving unnecessary intrapartum antibiotic prophylaxis (IAP).  
5. The addition of screening to risk-based prevention may reduce the incidence 
of EOGBS. However, a lack of high quality evidence on the benefits and 
harms of screening means that it is not possible to quantify the impact of 
universal GBS screening and assess whether IAP at such a large scale is a 
safe undertaking. 
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d. Long-term disability: 8.7-15.8% of surviving EOGBS cases.34-36 
e. Short-term EOGBS morbidity: Meningitis 13.2%; Sepsis 63.1%; Pneumonia 23.7%.3 
f. EOGBS cases with maternal risk factors: 33-37% of EOGBS cases will have at least one risk factor for intrapartum 
antibiotic prophylaxis.3  
 10 
References 
1. Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine 2013;31 Suppl 
4:D7-12. doi: 10.1016/j.vaccine.2013.01.009 [published Online First: 2013/08/30] 
2. O'Sullivan C, Lamagni T, Efstratiou A, et al. P3 Group B Streptococcal (GBS) disease in UK 
and Irish infants younger than 90 days, 2014–2015. Archives of disease in childhood 
2016;101(Suppl 1):A2-A2. doi: 10.1136/archdischild-2016-310863.3 
3. O’Sullivan C, Heath PT, on behalf of the British Pediatric Surveilance Unit. Group B 
Streptococcal (GBS) disease in UK and Irish infants younger than 90 days, 2014-2015, 
2016. 
4. National Institute for Health and Clinical Excellence. Antibiotics for early-onset neonatal 
infection: antibiotics for the prevention and treatment of early-onset neonatal 
infection. United Kingdom: National Institute for Health and Clinical Excellence, 
2012. 
5. Royal College of Obstetricians and Gynaecologists. Prevention of Early Onset Neonatal 
Group B Streptococcal Disease. Guideline No 36: RCOG, 2003. 
6. Royal College of Obstetricians and Gynaecologists. Prevention of Early Onset Neonatal 
Group B Streptococcal Disease. Green-top Guideline No. 36. 2 ed: Royal College of 
Obstetricians and Gynaecologists, 2012. 
7. Royal College of Obstetricians and Gynaecologists. Prevention of Early Onset Neonatal 
Group B Streptococcal Disease. Green-top Guideline No. 36. 3 ed: RCOG, 2017. 
8. Homer CS, Scarf V, Catling C, et al. Culture-based versus risk-based screening for the 
prevention of group B streptococcal disease in newborns: a review of national 
guidelines. Women and birth : journal of the Australian College of Midwives 
2014;27(1):46-51. doi: 10.1016/j.wombi.2013.09.006 [published Online First: 
2013/11/19] 
9. Rodriguez-Granger J, Alvargonzalez JC, Berardi A, et al. Prevention of group B 
streptococcal neonatal disease revisited. The DEVANI European project. Eur J Clin 
Microbiol Infect Dis 2012;31(9):2097-104. doi: 10.1007/s10096-012-1559-0 
[published Online First: 2012/02/09] 
 11 
10. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Maternal 
Group B Streptococcus in pregnancy: screening and management, C-Obs 19. 
Melbourne: RANZCOG, 2016. 
11. Money D, Allen VM. The prevention of early-onset neonatal group B streptococcal 
disease. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique 
et gynecologie du Canada : JOGC 2013;35(10):939-48. doi: 10.1016/s1701-
2163(15)30818-5 [published Online First: 2013/10/30] 
12. Money DM, Dobson S. The prevention of early-onset neonatal group B streptococcal 
disease. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique 
et gynecologie du Canada: JOGC 2004;26(9):826-40. 
13. Canadian Task Force on Preventive Health Care. Prevention of group B streptococcal 
infection in newborns: Recommendation statement from the Canadian Task Force 
on Preventive Health Care. CMAJ 2002;166(7):928-30. 
14. Melin P. Prevention of perinatal group B streptococcal diseases: Belgian guidelines. 
Round Table Series - Royal Society of Medicine 2007(85):29-41. 
15. Melin P, Verschraegen G, Mahieu L, et al. Towards a Belgian consensus for prevention of 
perinatal group B streptococcal disease. Indian Journal of Medical Research, 
Supplement 2004;119:197-200. 
16. Agence Nationale d’Accreditation et d’Evaluation en Sante. Antenatal prevention of 
early neonatal bacterial infection - Clinical Practice Guidelines. France: ANAES, 2001. 
17. Leitlinien der Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI), 
Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, Deutschen Gesellschaft 
für Pädiatrische Infektiologie (DGPI), et al. Prophylaxe der Neugeborenensepsis 
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